Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective ciprofol concentration to prevent cardiovascular response to tracheal intubation with remimazolam induction
ChiCTR2200063712Phase 4Not yet recruiting
- Sponsor
- Department of Anesthesiology, the First People's Hospital of Lianyungang City
- Start
- Oct 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ciprofol in None, sponsored by Department of Anesthesiology, the First People's Hospital of Lianyungang City. Primary endpoints: Intubation response after induction, ED50 of ciprofol for suppression of intubation cardiovascular response and 3 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
ciprofol
Beyond the preview
Go deeper on ChiCTR2200063712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063712.